EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Temporary mycophenolate discontinuation and reintroduction in pediatric kidney transplantation: predictors and long-term outcomes

Moran Plonsky Toder, Shirley Pollack, Rami Tibi, Irina Libinson-Zebegret, Renata Yakubov, Daniella Magen

Pediatric Nephrology · 2026-09 · 41 (9) · 3059-3067

DOI: 10.1007/s00467-026-07231-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Nephrology, online erschienen am 14.04.2026. Verfasst von Moran Plonsky Toder und 5 weiteren Autor:innen. Beteiligte Einrichtung: Technion - Israel Institute of Technology, The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel. m.plonsky@technion.ac.il. Hauptthemen laut MEDLINE: Mycophenolic Acid, Kidney Transplantation, Graft Rejection, Immunosuppressive Agents. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Technion - Israel Institute of Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Temporary discontinuation of mycophenolate mofetil (MMF) is frequently required in pediatric kidney transplant recipients, most often in response to viral complications. However, data regarding the long-term safety of MMF discontinuation, feasibility of reintroduction, and predictors of the need for MMF withdrawal in children remain limited.

Methods

We conducted a retrospective, single-center cohort study of pediatric kidney transplant recipients with longitudinal follow-up. Clinical, virologic, immunologic, and transplant-related data were collected. Outcomes included longitudinal estimated glomerular filtration rate (eGFR), biopsy-proven acute rejection, graft loss, de novo donor-specific antibody (dnDSA) development, unplanned hospitalization, and MMF reintroduction. Factors associated with MMF discontinuation were evaluated using multivariable regression analysis.

Results

Among 65 pediatric kidney transplant recipients, 22 (33.8%) required temporary MMF discontinuation, most commonly within the first post-transplant year. Opportunistic viral infections accounted for the majority of MMF withdrawal events, with BK virus as the predominant indication. MMF reintroduction was feasible in most patients (15/22). Longitudinal eGFR trajectories, rates of rejection, graft loss, dnDSA development, and unplanned hospitalization did not differ between patients who discontinued MMF and those who maintained full therapy. Younger age at transplantation emerged as the sole independent predictor of the need for MMF discontinuation.

Conclusions

In this real-world pediatric cohort, temporary MMF discontinuation, when clinically indicated, closely monitored, and followed by cautious reintroduction, was not associated with adverse long-term graft outcomes. Younger age at transplantation was associated with a higher likelihood of MMF discontinuation, supporting individualized immunosuppression strategies and proactive efforts to identify children at risk for viral-driven immunosuppression intolerance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycophenolic AcidKidney TransplantationGraft RejectionImmunosuppressive AgentsHumansFemaleChildMaleRetrospective StudiesAdolescentChild, PreschoolTreatment InterruptionGlomerular Filtration RateGraft SurvivalTreatment OutcomeFollow-Up StudiesOpportunistic InfectionsLongitudinal Studies

Stichwörter der Autor:innen

Graft survivalImmunosuppression reductionMycophenolate mofetilOpportunistic viral infectionsPediatric kidney transplantation

Substanzen

Mycophenolic AcidImmunosuppressive Agents

Autor:innen und Institutionen

  • Technion - Israel Institute of Technology, The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel. m.plonsky@technion.ac.il.
  • Rambam Health Care Campus, Ruth Rappaport Children's Hospital, Pediatric Nephrology Institute, Haifa, Israel. m.plonsky@technion.ac.il.
  • Technion - Israel Institute of Technology, The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel.
  • Rambam Health Care Campus, Ruth Rappaport Children's Hospital, Pediatric Nephrology Institute, Haifa, Israel.

Förderung

  • Technion - Israel Institute of Technology

Zitieren

APA

Plonsky Toder, M., Pollack, S., Tibi, R., Libinson-Zebegret, I., Yakubov, R., & Magen, D. (2026). Temporary mycophenolate discontinuation and reintroduction in pediatric kidney transplantation: predictors and long-term outcomes. Pediatric Nephrology, 41(9), 3059-3067. https://doi.org/10.1007/s00467-026-07231-8

Vancouver

Plonsky Toder M, Pollack S, Tibi R, Libinson-Zebegret I, Yakubov R, Magen D. Temporary mycophenolate discontinuation and reintroduction in pediatric kidney transplantation: predictors and long-term outcomes. Pediatric Nephrology. 2026;41(9):3059-3067. doi:10.1007/s00467-026-07231-8

BibTeX
@article{PlonskyToder2026,
  author = {Plonsky Toder, Moran and Pollack, Shirley and Tibi, Rami and Libinson-Zebegret, Irina and Yakubov, Renata and Magen, Daniella},
  title = {Temporary mycophenolate discontinuation and reintroduction in pediatric kidney transplantation: predictors and long-term outcomes},
  journal = {Pediatric Nephrology},
  year = {2026},
  volume = {41},
  number = {9},
  pages = {3059--3067},
  doi = {10.1007/s00467-026-07231-8}
}
Kostenlos starten →